Cellectis SA (CLLS)

15.14
+0.02(+0.13%)
  • Volume:
    61,629
  • Bid/Ask:
    15.12/15.17
  • Day's Range:
    14.91 - 15.20

CLLS Overview

Prev. Close
15.12
Day's Range
14.91-15.2
Revenue
119.67M
Open
14.85
52 wk Range
14.18-34.71
EPS
-2.66
Volume
61,629
Market Cap
650.29M
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
272,351
P/E Ratio
-
Beta
2.36
1-Year Change
-7.35%
Shares Outstanding
43,039,180
Next Earnings Date
Aug 04, 2021
What is your sentiment on Cellectis SA?
or
Vote to see community's results!

Cellectis SA News

Cellectis SA Analysis

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong BuyNeutralSellSellStrong Sell
Technical IndicatorsStrong BuyBuyNeutralStrong SellStrong Sell
SummaryStrong BuyNeutralNeutralStrong SellStrong Sell

Cellectis SA Company Profile

Cellectis SA Company Profile

Employees
340

Cellectis SA is a France-based company active in the field of genome engineering and genomic surgery. The Company specializes in the research, development, and commercialization of rational genome engineering technologies. The Company develops immunotherapies that aim to force the immune system to target and eradicate cancer cells. It has developed an expertise in combining meganucleases with engineered targeting Deoxyribonucleic Acid (DNA) matrices into Meganuclease Recombination Systems (MRS), used for gene excision, correction or replacement. Cellectis SA markets its technologies mainly for use in the research field, in pharmaceutical drug discovery programs, in the agronomics, bioproduction, and biotherapeutics fields. Cellectis SA operates several subsidiaries. The Company operates in France and the United States, among others.

Read More
  • All 7 analyst covering say "buy" with an average 12 month target price of $47.16. That's 161% ROI at it's current price of $18.08.
    0
    Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
    Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.